中文摘要：

目的观察CD56在t（8；21）初治成人急性髓系白血病（AML）患者中的表达，探讨其与临床特征和预后的关系。方法回顾性分析2008年1月至2014年4月收治的82例初治t（8；21）成人AML患者的临床资料，比较CD56阳性和阴性患者的临床特征及预后差异。结果82例患者中CD56阳性者50例，阴性者32例。对两组患者的性别、年龄、血常规、有无髓外浸润、染色体核型、早期病死率、完全缓解率及3年总生存率进行比较，差异均无统计学意义（P值均〉0．05）；阳性组患者CD19表达率较阴性组低（30．0％对53．1％，P=0．036），3年无病生存（DFS）率也较阴性组低（25．8％对46．9％，P=0．014），差异均有统计学意义。多因素分析结果显示CD56阳性是患者DFS的独立预后不良因素（HR=4．012，95％CI1．712～9．400，P=0．001）。结论CD56阳性合并t（8；21）初治成人AML患者预后不良。

英文摘要：

Objective To explore the clinical features and survival of patients with CD56 expression in de-novo acute myeloid leukemia （AML）with t （8;21 ）. Methods Clinical data of 82 de novo AML with t （8;21）who were newly diagnosed from Jan 2008 to Apr 2014 were analyzed retrospectively, 50 expressed CD56 and 32 not. Clinical characteristics and prognoses were compared between patients expressing and nonexpressing CD56. Results There were no statistically significant differences in terms of age, gender, white blood cell count （WBC）, percentage of bone marrow blasts, extramedullary infiltration rate, the early mortality or the presence of additional cytogenetic abnormalities between CD56^＋ and CD56^- groups （P〉 0.05）. The expressions of lymphatic antigens CD19 between CD56^＋ and CD56^- groups showed significant difference （30.0% vs 53.1%, P=0.036）. The complete remission and 3-year overall survival （OS）showed no significant differences between CD56^＋ and CD56^- groups, while 3-year disease-free survival （DFS）showed significant differences （25.8% vs 46.9%, P= 0.014）. Multivariable analysis for DFS identified CD56 positivity as an independent predictor. DFS of who received allogeneic hematopoietic stem cell transplantation （HSCT）was better than those treated with intermediate-dose cytarabine/high dose cytarabine （IDAC）as postremission therapy. Conclusion The expression of CD56 in de-novo AML with t（ 8;21 ） appeared to be associated with poorer prognosis.